Innate Pharma reports preliminary Phase I clinical data for IPH 2101 (a novel, anti-KIR monoclonal antibody activating NK cells) at the ASCO meeting

IPH 2101 was very well tolerated at all tested doses; the pharmacodynamic endpoint was met First Phase II trial with IPH 2101 used as a single agent in multiple myeloma to begin in 2009 Available on line: Poster on Phase I trial in Multiple Myeloma (preliminary data) Poster on Phase I trial in Acute Myeloid Leukemia (preliminary data) Subscribe to our newsletter Contact us 117, Avenue de Luminy - BP 30191 13 009 Marseille FRANCE +33 (0)4 30 30 30 30

The release as fetched from its publisher. innate-pharma.com ↗